Dashboard
Manage Tickers

RARE


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

td-cowen-maintains-buy-on-ultragenyx-pharmaceutical-lowers-price-target-to-75
TD Cowen Maintains Buy on Ultragenyx Pharm...
11/05/2025 18:50:38

TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from ...

truist-securities-maintains-buy-on-ultragenyx-pharmaceutical-lowers-price-target-to-90
Truist Securities Maintains Buy on Ultrage...
11/05/2025 16:45:19

Truist Securities analyst Joon Lee maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
11/05/2025 12:05:48

ultragenyx-pharmaceutical-announces-400m-sale-of-additional-25-royalty-interest-from-kyowa-kirin-on-future-sales-of-crysvita-in-us-canada-to-omers
Ultragenyx Pharmaceutical Announces $400M ...
11/04/2025 21:13:46

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of ...

ultragenyx-pharmaceutical-affirms-fy2025-sales-guidance-of-640000m-670000m-vs-657157m-est
Ultragenyx Pharmaceutical Affirms FY2025 S...
11/04/2025 21:11:09

2025 Financial GuidanceUltragenyx reaffirmed its revenue guidance for 2025. Total revenues are expected to grow approximately 1...

ultragenyx-pharmaceutical-q3-eps-181-misses-125-estimate-sales-159933m-miss-166709m-estimate
Ultragenyx Pharmaceutical Q3 EPS $(1.81) M...
11/04/2025 21:10:17

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.81) per share which missed the analyst consensus estim...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

ultragenyx-doses-first-patient-in-aurora-study-evaluating-gtx-102-in-additional-angelman-syndrome-genotypes-and-age-groups
Ultragenyx Doses First Patient In Aurora S...
10/30/2025 12:05:20

ionis-pharmaceuticals-to-expedite-development-of-rare-neurological-disease-candidate-with-fda-breakthrough-status
Ionis Pharmaceuticals To Expedite Developm...
09/09/2025 17:51:26

FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.

hc-wainwright--co-reiterates-buy-on-ultragenyx-pharmaceutical-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Ultr...
09/09/2025 10:16:42

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and maintai...

ultragenyx-reports-96-week-phase-3-results-for-dtx401-in-gsdia-showing-greater-reductions-in-cornstarch-use-and-sustained-glycemic-control
Ultragenyx Reports 96-Week Phase 3 Results...
09/08/2025 20:18:59

At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglyc...

assessing-ultragenyx-pharmaceutical-insights-from-8-financial-analysts
Assessing Ultragenyx Pharmaceutical: Insig...
09/05/2025 14:01:03

cantor-fitzgerald-reiterates-overweight-on-ultragenyx-pharmaceutical-maintains-105-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/05/2025 13:44:07

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains ...

fda-outlines-process-to-speed-up-rare-disease-therapy-approvals
FDA Outlines Process To Speed Up Rare Dise...
09/04/2025 18:50:03

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
09/02/2025 17:35:29

ultragenyx-initiates-rolling-submission-of-a-biologics-license-application-to-the-fda-for-its-dtx401-aav-gene-therapy-in-glycogen-storage-disease-type-ia
Ultragenyx Initiates Rolling Submission Of...
08/18/2025 12:04:53

canaccord-genuity-maintains-buy-on-ultragenyx-pharmaceutical-lowers-price-target-to-128
Canaccord Genuity Maintains Buy on Ultrage...
08/08/2025 21:36:37

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price tar...

8-analysts-assess-ultragenyx-pharmaceutical-what-you-need-to-know
8 Analysts Assess Ultragenyx Pharmaceutica...
08/06/2025 22:01:05

cantor-fitzgerald-maintains-overweight-on-ultragenyx-pharmaceutical-lowers-price-target-to-105
Cantor Fitzgerald Maintains Overweight on ...
08/06/2025 14:17:39

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the ...

ultragenyx-pharmaceutical-affirms-fy2025-sales-guidance-of-64000m-67000m-vs-65327m-est
Ultragenyx Pharmaceutical Affirms FY2025 S...
08/05/2025 20:02:45

Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2025 sales outlook from $640.00 million-$670.00 million to $640.00 million-$6...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION